KR20230124624A - 에피나스틴 또는 그의 염을 함유하는 도포 투여용 의약조성물 - Google Patents

에피나스틴 또는 그의 염을 함유하는 도포 투여용 의약조성물 Download PDF

Info

Publication number
KR20230124624A
KR20230124624A KR1020237024025A KR20237024025A KR20230124624A KR 20230124624 A KR20230124624 A KR 20230124624A KR 1020237024025 A KR1020237024025 A KR 1020237024025A KR 20237024025 A KR20237024025 A KR 20237024025A KR 20230124624 A KR20230124624 A KR 20230124624A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
epinastine
salt
acid
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237024025A
Other languages
English (en)
Korean (ko)
Inventor
나오키 오구라
유 가지와라
고시 후지사와
요시히코 에사키
고지 사카나카
도요미 후지사와
유코 도네
Original Assignee
산텐 세이야꾸 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 산텐 세이야꾸 가부시키가이샤 filed Critical 산텐 세이야꾸 가부시키가이샤
Publication of KR20230124624A publication Critical patent/KR20230124624A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237024025A 2020-12-24 2021-12-23 에피나스틴 또는 그의 염을 함유하는 도포 투여용 의약조성물 Pending KR20230124624A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JPJP-P-2020-215231 2020-12-24
JP2020215231 2020-12-24
JP2021146903 2021-09-09
JPJP-P-2021-146903 2021-09-09
PCT/JP2021/047886 WO2022138826A1 (ja) 2020-12-24 2021-12-23 エピナスチン又はその塩を含有する塗布投与用医薬組成物

Publications (1)

Publication Number Publication Date
KR20230124624A true KR20230124624A (ko) 2023-08-25

Family

ID=82158673

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237024025A Pending KR20230124624A (ko) 2020-12-24 2021-12-23 에피나스틴 또는 그의 염을 함유하는 도포 투여용 의약조성물

Country Status (7)

Country Link
US (1) US20240074973A1 (https=)
EP (1) EP4268827A4 (https=)
JP (2) JP7124248B1 (https=)
KR (1) KR20230124624A (https=)
AU (1) AU2021410145A1 (https=)
TW (1) TW202241449A (https=)
WO (1) WO2022138826A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025205960A1 (ja) * 2024-03-27 2025-10-02 参天製薬株式会社 エピナスチン又はその塩を含有する経皮投与用医薬組成物と抗アレルギー薬との組み合わせ

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064817A1 (ja) 2003-01-22 2004-08-05 Nichiban Co., Ltd. 眼疾患治療用経皮吸収型製剤、その使用、及び眼疾患治療薬の眼の局所組織への移行方法
WO2007007851A1 (en) 2005-07-08 2007-01-18 Senju Pharmaceutical Co., Ltd. Percutaneously absorptive ophthalmic preparation comprising epinastine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536816A (en) * 1964-09-30 1970-10-27 Atlas Chem Ind Water-in-oil emulsion
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US20040247686A1 (en) * 2003-04-04 2004-12-09 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
JP5021155B2 (ja) * 2003-08-01 2012-09-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング エピナスチンと１種以上のさらなる抗−ｈ１−ヒスタミン類との組合せを含む皮膚疾患治療用製薬組成物
WO2005089803A2 (en) * 2004-03-24 2005-09-29 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs
CN101036659A (zh) * 2006-03-13 2007-09-19 张文静 一组盐酸依匹斯汀制剂及其制备方法
EP2056809A1 (en) * 2006-08-28 2009-05-13 Senju Pharmaceutical Co., Ltd. Ophthalmic percutaneous absorption type preparation
US20080194544A1 (en) * 2007-02-08 2008-08-14 Ramesh Krishnamoorthy Aqueous formulations of epinastine for treating allergic rhinitis
KR20240023714A (ko) * 2015-02-02 2024-02-22 산텐 세이야꾸 가부시키가이샤 폴리아프론 및 이의 안검 투여
JP6134853B1 (ja) * 2016-10-28 2017-05-24 参天製薬株式会社 エピナスチン含有点眼液
JP7355539B2 (ja) * 2018-07-20 2023-10-03 ロート製薬株式会社 眼科組成物
JP7458159B2 (ja) * 2018-09-28 2024-03-29 ロート製薬株式会社 眼科組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064817A1 (ja) 2003-01-22 2004-08-05 Nichiban Co., Ltd. 眼疾患治療用経皮吸収型製剤、その使用、及び眼疾患治療薬の眼の局所組織への移行方法
WO2007007851A1 (en) 2005-07-08 2007-01-18 Senju Pharmaceutical Co., Ltd. Percutaneously absorptive ophthalmic preparation comprising epinastine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
알레지온(등록상표) LX 점안액 0.1% 의약품 인터뷰 폼

Also Published As

Publication number Publication date
WO2022138826A1 (ja) 2022-06-30
JP7124248B1 (ja) 2022-08-23
TW202241449A (zh) 2022-11-01
EP4268827A4 (en) 2024-12-11
JP2022160664A (ja) 2022-10-19
US20240074973A1 (en) 2024-03-07
AU2021410145A1 (en) 2023-07-27
JPWO2022138826A1 (https=) 2022-06-30
AU2021410145A9 (en) 2024-07-25
EP4268827A1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
RU2639472C2 (ru) Офтальмическая композиция
JP5441058B2 (ja) 四級アンモニウム化合物を含む組成物
CA3056395C (en) Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
JP6259042B2 (ja) タペンタドールを含む半固形の水性医薬組成物
JP5722802B2 (ja) プロスタグランジンを含有するアニオン性水中油型エマルジョンおよびその使用
GR1009040B (el) Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
US20190216767A1 (en) Topical therapy for the treatment of skin keratoses using nanoparticles of taxanes
EP3727335A1 (en) Ocular drug delivery
JP7171971B1 (ja) エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物
TW201904562A (zh) 倍氯松的水包油奈米乳液組成物
JP5722803B2 (ja) プロスタグランジンを含有するカチオン性水中油型エマルジョンおよびその使用
JP7124248B1 (ja) エピナスチン又はその塩を含有する塗布投与用医薬組成物
KR20160096376A (ko) 히알루론산, 미네랄 오일 및 계면활성제를 포함하는 안과용 조성물
CN116669705A (zh) 含有依匹斯汀或其盐的涂布施予用医药组合物
JP7124234B2 (ja) フェノルドパムの安定な局所用組成物
HK40097614A (en) Pharmaceutical composition for topical administration containing epinastine or salt thereof
HK40091801A (zh) 含有依匹斯汀或其盐的涂布施予用医药组合物
JP2025036319A (ja) クロルフェニラミンマレイン酸塩を含有する医薬組成物
WO2025205960A1 (ja) エピナスチン又はその塩を含有する経皮投与用医薬組成物と抗アレルギー薬との組み合わせ
WO2025092809A1 (zh) 稳定性改善的苯酚衍生物的药物组合物及其用途
HK1166608B (en) Anionic oil-in-water emulsions containing prostaglandins and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230714

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241212

Comment text: Request for Examination of Application